Clinical Trials

466 enrolled

Ovarian Neoplasms

NCT07213804 2026-05-27

FRAmework-01

1,080 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT06843447 2026-05-26

MK-5909-003

Phase 1/2 Recruiting

460 enrolled

Ovarian Cancer Recurrent

NCT06161025 2026-05-22

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

860 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06312176 2026-05-22

MK-2870-010

1,200 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

220 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

30 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT07194044 2026-05-15

METTSEO

15 enrolled

Sarcoma

Sarcoma, Ewing

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

115 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05864534 2026-05-13

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

25 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT06023862 2026-05-06

DOVE

198 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06434064 2026-04-24

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06994195 2026-04-20

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

384 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

257 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT04516447 2026-04-07

MUIR

172 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06072781 2026-04-02

RAMP 301

270 enrolled

Low Grade Serous Ovarian Cancer

NCT05210374 2026-03-27

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

24 enrolled

Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT05748834 2026-03-20

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

36 enrolled

Breast

Breast Neoplasms

NCT05610735 2026-03-19

Combination Therapy for Recurrent Ovarian Cancer

Phase 1/2 Recruiting

72 enrolled

Ovarian Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

186 enrolled